Article
Amgen and Novartis back Aimovig with new data as migraine competition heats up
Rating:
0.0
Views:
139
Likes:
1
Library:
1
Facing a slew of competitors, Amgen and Novartis are marching out new Phase IV results to bolster Aimovig, their first-to-market CGRP inhibitor for migraine prevention. The results come about a year and a half after the drug was panned by a group of medical experts who convened at UnitedHealth Group's
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value